 |
|
Efficacy of low-dose spironolactone on top of angiotensin receptor blockade in patients with glomerulonephritis
Byung Chul Yu, Min Sung Lee, Jong Joo Moon, Soo Jeong Choi, Jin Kuk Kim, Seung Duk Hwang, Moo Yong Park
Kidney Res Clin Pract. 2018;37(3):257-265. Published online 2018 Sep 30 DOI: https://doi.org/10.23876/j.krcp.2018.37.3.257
|
|
Citations to this article as recorded by
 Drug repurposing for glomerular diseases: an underutilized resource
Monica Suet Ying Ng, Gursimran Kaur, Ross S. Francis, Carmel M. Hawley, David W. Johnson
Nature Reviews Nephrology.2024; 20(11): 707. CrossRef Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease
Teena Zachariah, Jai Radhakrishnan
Clinical Journal of the American Society of Nephrology.2024; 19(11): 1499. CrossRef Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes
Ako Oiwa, Dai Hiwatashi, Teiji Takeda, Takahide Miyamoto, Iori Kawata, Masayoshi Koinuma, Masanori Yamazaki, Mitsuhisa Komatsu
The Journal of Clinical Endocrinology & Metabolism.2023; 108(9): 2203. CrossRef The mineralocorticoid receptor in chronic kidney disease
Jonatan Barrera‐Chimal, Frédéric Jaisser, Hans‐Joachim Anders
British Journal of Pharmacology.2022; 179(13): 3152. CrossRef Role of mineralocorticoid receptor antagonists in kidney diseases
Vishal Patel, Amit Joharapurkar, Mukul Jain
Drug Development Research.2021; 82(3): 341. CrossRef Mineralocorticoid receptor blockade for renoprotection
Dae Ryong Cha
Kidney Research and Clinical Practice.2018; 37(3): 183. CrossRef
|